Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.64 |
| ▸ | MPO | P05164 | 12/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25397483 | 1.00 | HTR2A (0.69) | HTR2AHTR2CGPR84MPONR3C1 | |
| SCHEMBL27837972 | 0.88 | HTR2A (0.69) | HTR2AHTR2CGPR84MPONR3C1 | |
| SCHEMBL22923386 | 0.84 | HTR2A (0.77) | HTR2AHTR2CGPR84MPONR3C1 | |
| SCHEMBL26054201 | 0.84 | HTR2A (0.55) | HTR2AHTR2CNR3C1HTR1ASLC6A4 | |
| SCHEMBL25332457 | 0.83 | HTR2A (0.67) | HTR2AHTR2CGPR84MPOTRPM8 | |
| SCHEMBL24912887 | 0.82 | HTR2A (0.61) | HTR2AHTR2CGPR84MPONR3C1 | |
| SCHEMBL21292855 | 0.82 | HTR2A (0.61) | HTR2AHTR2CGPR84MPONR3C1 | |
| SCHEMBL20242715 | 0.82 | HTR2A (0.61) | HTR2AHTR2CGPR84MPONR3C1 | |
| SCHEMBL29316405 | 0.82 | HTR2A (0.61) | HTR2AHTR2CGPR84MPONR3C1 | |
| SCHEMBL27220727 | 0.82 | HTR2A (0.61) | HTR2AHTR2CGPR84MPONR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | HTR2A 13/4885HTR2C 23/4885GPR84 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.